Julio Núñez Villota
Julio Núñez Villota, MD, PhD, FESC is an expert in Cardiology at Hospital Clínico Universitario de Valencia (Spain). As of October 2026, ScienceLeadR ranks Julio Núñez Villota in the top 1% of experts worldwide for Heart Failure. Julio Núñez Villota has authored 71 publications, the most recent in 2026, and is an investigator in 37 clinical trials, 17 of them ongoing. SLR score: 1,014 (community average: 125). How the SLR is computed.
LeadR Profile
Cardiology
Subspecialties: Public Health - Pharmacy - Biochemistry
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2017 - 2026
Number : 71
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide. PMID 41879224 — lipoproteins, cardiovascular diseases, cholesterol, history, lipoprotein(a), apolipoproteins | N Engl J Med Top journal | 2026 | 2 |
| The effect of vericiguat on sudden cardiac death: insights from the VICTOR trial. PMID 41874280 — heart failure, death, sudden, cardiac | Eur J Heart Fail | 2026 | 1 |
| Integrated care for COPD and cardiovascular comorbidities: A multidisciplinary approach for the cardiopulmonary patient. PMID 41558139 — comorbidity, emergency medicine, pulmonary disease, chronic obstructive | Semergen | 2026 | 0 |
| Antigen carbohydrate 125 as a prognostic biomarker in patients with stable chronic heart failure. PMID 41509622 — mortality, incidence, heart failure, heart, biomarkers, heart failure, systolic, carbohydrates, prognosis, plasma | Cardiovasc Diagn Ther | 2025 | 0 |
| Mechanistic Basis for Differential Effects of Interatrial Shunt Treatment in HFrEF vs HFpEF: The RELIEVE-HF Trial. PMID 40892630 — heart failure, heart, heart failure, diastolic, vena cava, inferior, signs and symptoms, heart failure, systolic, echocardiography, therapeutics, atrial shunt | JACC Cardiovasc Imaging | 2025 | 0 |
Clinical Studies 37
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Ongoing Clinical Trials
17 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| HF POLARIS A research study to look at how well NNC0487 0111 works compared to placebo in people with heart failure and obesity 2025-523717-29-00 — mortality, safety, heart failure, heart, heart failure, diastolic, obesity, morbidity, research | Phase 3 | Recruiting | 2026 |
| A study to test whether vicadrostat (BI 690517) in combination with empagliflozin helps people with heart failure and a weak pumping function of the left side of the heart 2024-519525-38-00 — safety, heart failure, heart | Phase 3 | Not yet recruiting | 2025 |
| Lp(a) lowering study of pelacarsen (TQJ230) with background inclisiran in participants with elevated Lp(a) and established ASCVD 2024-516356-18-00 — safety, cardiovascular diseases | Phase 3 | Recruiting | 2026 |
| 202301CPC Redefine HF 2023-508581-15-00 — mortality, safety, heart failure, heart, morbidity | Phase 3 | Recruiting | 2024 |
| A study to test whether vicadrostat (BI 690517) in combination with empagliflozin helps people with heart failure 2023-509706-30-00 — safety, heart failure, heart | Phase 3 | Recruiting | 2024 |
LeadR Networks
Main global connection map